Track topics on Twitter Track topics that are important to you
Lodotra Rheumatoid Arthritis PubMed articles on BioPortfolio. Our PubMed references draw on over 21 million records from the medical literature. Here you can see the latest Lodotra Rheumatoid Arthritis articles that have been published worldwide.
We have published hundreds of Lodotra Rheumatoid Arthritis news stories on BioPortfolio along with dozens of Lodotra Rheumatoid Arthritis Clinical Trials and PubMed Articles about Lodotra Rheumatoid Arthritis for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Lodotra Rheumatoid Arthritis Companies in our database. You can also find out about relevant Lodotra Rheumatoid Arthritis Drugs and Medications on this site too.
Rheumatoid arthritis is associated with an increased cardiovascular risk, secondary to endothelial dysfunction. There is accumulating evidence that methotrexate reduces cardiovascular risk in rheumatoid arthritis, but the mechanisms involved are still unknown. In this study, we aimed to determine the effect of methotrexate on endothelial function and traditional cardiovascular risk factors in the adjuvant-induced arthritis (AIA) rat model.
To explore the role of TNF-α in the peripheral blood of patients with rheumatoid arthritis (RA) and its underlying mechanism.
Chronic inflammation of rheumatoid arthritis (RA) is associated with disturbances in muscle and bone metabolism.
Interferon alpha-induced arthritis and activation of the type 1 interferon pathway during rheumatoid arthritis (RA) has been well documented but the underlying mechanism remains unclear. This study addressed the binding specificity of antibodies with recombinant interferon alpha 2b (rIFN -2b) in sera from different RA patients. Utilization of anti-hrIFN -2b antibodies as a probe for estimation of interferon -2b concentration in RA patients' synovial fluid (SF) was also investigated.
Treat-to-target implementation in rheumatoid arthritis (RA) requires a shared decision making (SDM) process. However, ability to pay is a major determinant of patient choice, but how this factor affects SDM is under explored.
Rheumatoid Arthritis (RA) is a chronic inflammatory disease that has a major impact on patients´ quality of life. The Rheumatoid Arthritis Quality of Life (RAQoL) questionnaire is a patient-reported outcome measure, specific to RA. The aim of this study was to translate and perform the cross-cultural adaptation of the RAQoL into Portuguese.
Distinguishing of rheumatoid arthritis (RA) and Lyme arthritis (LA) is difficult, because of similar symptoms. This presents a significant clinical problem since treatments are quite different in both diseases. We investigated the plasma phospholipid profiles of RA and LA patients versus healthy subjects to find metabolic changes responsible for differentiation of both diseases.
Collagen antibodies in serum are involved in the pathogenesis of Rheumatoid Arthritis (RA). The objective of this study was to identify the subtype of collagen antibodies and T cell subtype distribution in pristane-induced arthritis (PIA) and to clarify their roles in the initiation and maintenance of arthritis.
The objective of the present study was to evaluate the role of CDKN1A in rheumatoid arthritis (RA).
To estimate total costs among patients with rheumatoid arthritis (RA) who persisted on or switched from newly initiated biologic therapy.
Recent advances in knowledge of the pathogenesis of rheumatoid arthritis (RA) has led to promoting very early intervention.
The aim of this descriptive study was to determine whether people with rheumatoid arthritis (RA) wear adequately fitting footwear.
Biologic disease-modifying antirheumatic drugs (bDMARDs) have revolutionised treatment and outcomes for rheumatoid arthritis (RA). The expanding repertoire allows the option of switching bDMARD if current treatment is not effective. For some patients, even after switching, disease control remains elusive. This analysis aims to quantify the frequency of, and identify factors associated with, bDMARD refractory disease.
Neoangiogenesis is a crucial event to promote the development of the hyperplasic proliferative pathologic synovium in Rheumatoid arthritis (RA). Ultrasound (US) is sensitive for detection of power Doppler (PD) vascularization.
To investigate the relationship between bioimpedance-derived total body fat percentage, waist circumference (WC) and Body Mass Index (BMI) and the subsequent development of rheumatoid arthritis (RA).
Rheumatoid arthritis is an inflammatory polyarthritis that frequently affects the hands and wrists. Hand exercises are prescribed to improve mobility and strength, and thereby hand function.
The aim of this study was to identify potential key candidate genes and uncover their potential mechanisms in rheumatoid arthritis.
Microbial communities inhabiting the human body, collectively called the microbiome, are critical modulators of immunity. This notion is underpinned by associations between changes in the microbiome and particular autoimmune disorders. Specifically, in rheumatoid arthritis, one of the most frequently occurring autoimmune disorders worldwide, changes in the oral and gut microbiomes have been implicated in the loss of tolerance against self-antigens and in increased inflammatory events promoting the damage of...
Rheumatoid arthritis (RA) is a chronic inflammatory systemic autoimmune disease, affecting the joints with varying severity among patients. The risk factors include age, gender, genetics and environmental exposure (cigarette smoking, air pollutants and occupational). Many complications can follow such as permanent joint damage requiring arthroplasty, rheumatoid vasculitis and elty's syndrome requiring splenectomy if it remains unaddressed. As there is no cure for RA, the treatment goals are to reduce the pa...
Dysregulated immune function in rheumatoid arthritis (RA) might lead to the development of myelodysplastic syndrome (MDS). Serum interleukin-6 (IL-6) concentrations are increased in both RA and MDS patients.
To evaluate adherence to newly initiated biologic disease-modifying antirheumatic drugs (bDMARDs) in effectively treated patients with rheumatoid arthritis (RA).
Early treatment ensures optimal outcomes in rheumatoid arthritis (RA). This study aimed to quantify treatment delays in RA patients and to explore factors influencing delay and resultant patient outcomes.
Multiple studies have observed seemingly unfavorable changes in lipid profiles associated with IL6 receptor antagonists (IL-6R) and some other rheumatoid arthritis (RA) therapies. The real-world cardiovascular disease (CVD) risk associated with the first approved anti IL-6R medication for RA, tocilizumab, remains uncertain.
Hansen disease is an infectious chronic disease with various clinical manifestations. Its joint performance may easily mimic rheumatoid arthritis.
To assess differences in initial treatment and treatment response in male and female patients with rheumatoid arthritis (RA) in daily clinical practice.